Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C, Chronic
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a…
- Trial name
- NCT00062816
- Testing
- ISIS 14803, peginterferon alfa, ribavirin
- Where
- 25 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hepatitis C, Hepatitis
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously…
- Trial name
- NCT00088504
- Testing
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Where
- 67 sites in United States
- Volunteers
- 315 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis c
Glecaprevir/Pibrentasvir Real-world Study in China
To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study
- Trial name
- NCT03941821
- Testing
- Glecaprevir/Pibrentasvir
- Volunteers
- 800 people
- Sponsor
- Tongji Hospital
Hepatitis C
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures
The purpose of this study is to evaluate the efficacy and safety of triple therapy of AbbVie adults with chronic hepatitis C virus ("HCV"), who have not responded to prior treatment with protease inhibitors.
- Trial name
- NCT02646111
- Testing
- 12 weeks without Ribavirin, 12 weeks with Ribavirin, 24 weeks with Ribavirin
- Volunteers
- 120 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hepatitis C, Chronic, Hepacivirus
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)
The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness.
- Trial name
- NCT00705263
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 113 people
- Sponsor
- Schering-Plough
Hepatitis C
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
The purpose of this study is to see which of two doses of PEG (polyethylene glycol) interferon alfa-2b in combination with Ribavirin for 48 weeks is more effective at elimination of hepatitis C.
- Trial name
- NCT00207363
- Testing
- Ribavirin, Peg interferon alfa 2b, induction therapy
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C, Chronic
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
The primary objective of this pilot trial is to compare the efficacy, measured as sustained virologic response (SVR) at least 12 weeks after completion of therapy, across three study regimens/delivery modalities: Arm 1 - 4 weeks…
- Trial name
- NCT03480932
- Testing
- Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatitis C
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
The study evaluates safety and efficacy of vaniprevir (MK7009), when administered with Pegylated-Interferon (peg-IFN) and Ribavirin, in Japanese patients with Hepatitis C infection.
- Trial name
- NCT00880763
- Testing
- Vaniprevir, Pegylated Interferon (peg-IFN), Ribavirin
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
The purpose of this study is to assess antiviral activity when administered alone for 3 days or in combination with peginterferon and ribavirin for 12 weeks.
- Trial name
- NCT00911963
- Testing
- peginterferon alfa-2a, ribavirin
- Where
- 10 sites in United States, Argentina and 2 more
- Volunteers
- 49 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic, Substance Use Disorders
Linkage to Care for Persons With Hep C Infection
Hepatitis C Virus (HCV) infection is an ongoing challenge in the United States, with an estimated 2.4 million individuals living with HCV in 2016.
- Trial name
- NCT05397067
- Testing
- Peer specialist (PS), Incentives, telehealth visits
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Carilion Clinic
Chronic Hepatitis C (CHC)
A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)
This is a study designed to compare the safety and efficacy of 3 different doses of grazoprevir (MK-5172) combined with pegylated interferon alfa-2b (PEG-IFN) and ribavirin (RBV) in treatment-naïve participants with genotype 1…
- Trial name
- NCT01710501
- Testing
- Grazoprevir, pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 87 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
The purpose of this observational study was to provide summary data from participants who relapsed at the end of the follow-up phase after 24 weeks of treatment with standard care PegIntron plus ribavirin in Part 1 of the study…
- Trial name
- NCT01054742
- Testing
- Standard of Care PegIntron, Standard of Care Ribavirin
- Volunteers
- 2 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated.
- Trial name
- NCT02112942
- Testing
- IDX21459
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir fixed dose combination (FDC) with or without ribavirin (RBV) administered for 12 or 24 weeks in treatment-experienced subjects…
- Trial name
- ION-2 (NCT01768286)
- Testing
- LDV/SOF, RBV
- Where
- 53 sites in United States
- Volunteers
- 441 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to…
- Trial name
- ACTIVATE (NCT01364090)
- Testing
- Pegylated interferon alfa 2b, Ribavirin
- Where
- 17 sites in Australia, Belgium and 5 more
- Volunteers
- 93 people
- Sponsor
- Kirby Institute
Chronic Hepatitis, C Virus
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.
The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral…
- Trial name
- NCT02950870
- Testing
- Ombitasvir-Paritaprevir-Ritonavir, Dasabuvir, Ribavirin
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- University of Modena and Reggio Emilia
Hepatitis C, Chronic
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons.
- Trial name
- NCT01054573
- Testing
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 90 people
- Sponsor
- Janssen Infectious Diseases BVBA
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
The purpose of this Phase 2, open-label, 2-part, multicenter study was to evaluate the efficacy, safety, and pharmacokinetics of co-administration of ABT-493 and ABT-530 with and without ribavirin (RBV) at different doses in…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV
- Trial name
- NCT02243280
- Testing
- ABT-493, ABT-530
- Volunteers
- 174 people
- Sponsor
- AbbVie
Hepatitis C
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received…
- Trial name
- NCT01446250
- Testing
- Alisporivir, Boceprevir, Peginterferon alfa-2a
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic, Cirrhosis
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2.
- Trial name
- NCT02113631
- Testing
- Telaprevir, Boceprevir, Peg-IFN
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Louis Stokes VA Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.